Clinicopathologic characteristics of EGFR, KRAS, and ALK alterations in 6,595 lung cancers

<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368 · see citing works

Comprehensive molecular profiling of lung adenocarcinoma

The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13385 · Cited by 5,732 · see citing works

Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

Kwak, E. L., Bang, Y., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S. I., Dezube, B. J., Janne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,442 · see citing works

Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527 · cited 1× · see citing works

Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK

Shaw, A. T., Yeap, B. Y., Mino-Kenudson, M. A., Digumarthy, S. R., Costa, D. B., Heist, R. S., Solomon, B., Stubbs, H., Admane, S., McDermott, U., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.6993 · Cited by 1,873 · see citing works

A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non–Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER)

Shi, Y., Au, J. S. K., Thongprasert, S., Srinivasan, S., Tsai, C., Khoa, M. T., Heeroma, K., Itoh, Y., Cornelio, G. H., & Yang, P. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000033 · Cited by 1,554 · see citing works

Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology

Lindeman, N. I., Cagle, P. T., Beasley, M. B., Chitale, D. A., Dacic, S., Giaccone, G., Jenkins, R. B., Kwiatkowski, D. J., Saldivar, J.-S., Squire, J., et al. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318290868f · Cited by 1,280 · see citing works

EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer

Koivunen, J. P., Mermel, C. H., Zejnullahu, K., Murphy, C., Lifshits, E., Tisch, A. H., Choi, H. G., Kim, J., Chiang, D. Y., Thomas, R. K., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0168 · Cited by 992 · see citing works

The EML4‐ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild‐type EGFR and KRAS

Wong, D. W., Leung, E. L., So, K. K., Tam, I. Y. S., Sihoe, A. D., Cheng, L., Ho, K., Au, J. S. K., Chung, L., & Wong, M. P. (2009) · Cancer · doi:10.1002/cncr.24181 · Cited by 720 · see citing works

TPM3-ALK and TPM4-ALK Oncogenes in Inflammatory Myofibroblastic Tumors

Lawrence, B. D., Pérez‐Atayde, A. R., Hibbard, M. K., Rubin, B. P., Cin, P. D., Pinkus, J. L., Pinkus, G. S., Xiao, S., Yi, E. S., Fletcher, C. D. �., et al. (2000) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64550-6 · Cited by 710 · see citing works

Unique Clinicopathologic Features Characterize ALK -Rearranged Lung Adenocarcinoma in the Western Population

Rodig, S. J., Mino-Kenudson, M. A., Đačić, S., Yeap, B. Y., Shaw, A. T., Barletta, J. A., Stubbs, H., Law, K., Lindeman, N. I., Mark, E. J., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0802 · Cited by 677 · see citing works

Molecular Epidemiology of <i>EGFR</i> and <i>KRAS</i> Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related <i>KRAS</i> -Mutant Cancers

Dogan, S., Shen, R., Ang, D. C., Johnson, M. L., D'Angelo, S. P., Paik, P. K., Brzostowski, E. B., Riely, G. J., Kris, M. G., Zakowski, M. F., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3265 · Cited by 639 · see citing works

ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS : An Analysis of 1,683 Patients with Non–Small Cell Lung Cancer

Gainor, J. F., Varghese, A. M., Ou, S. I., Kabraji, S. K., Awad, M. M., Katayama, R., Pawlak, A. C., Mino-Kenudson, M. A., Yeap, B. Y., Riely, G. J., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0318 · Cited by 609 · see citing works

Presence ofEpidermal Growth Factor ReceptorGene T790M Mutation as a Minor Clone in Non–Small Cell Lung Cancer

Inukai, M., Toyooka, S., Ito, S., Asano, H., Ichihara, S., Soh, J., Suehisa, H., Ouchida, M., Aoe, K., Aoe, M., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1951 · Cited by 450 · see citing works

EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset

Inamura, K., Takeuchi, K., Togashi, Y., Hatano, S., Ninomiya, H., Motoi, N., Mun, M., Sakao, Y., Okumura, S., Nakagawa, K., et al. (2009) · Modern Pathology · doi:10.1038/modpathol.2009.2 · Cited by 442 · see citing works

Distinct Epidermal Growth Factor Receptor and KRAS Mutation Patterns in Non–Small Cell Lung Cancer Patients with Different Tobacco Exposure and Clinicopathologic Features

Tam, I. Y. S., Chung, L.-P., Suen, W., Wang, E., Wong, M. C. M., Ho, K. K., Lam, W. K., Chiu, S. W., Girard, L., Minna, J. D., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1981 · Cited by 400 · see citing works

Lung Adenocarcinoma: Modification of the 2004 WHO Mixed Subtype to Include the Major Histologic Subtype Suggests Correlations Between Papillary and Micropapillary Adenocarcinoma Subtypes, EGFR Mutations and Gene Expression Analysis

Motoi, N., Szőke, J., Riely, G. J., Seshan, V., Kris, M. G., Rusch, V. W., Gerald, W. L., & Travis, W. D. (2008) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e31815cb162 · Cited by 368 · see citing works

Clinicopathologic Features of Non-Small-Cell Lung Cancer with EML4–ALK Fusion Gene

Takahashi, T., Sonobe, M., Kobayashi, M., Yoshizawa, A., Menju, T., Nakayama, E., Mino, N., Iwakiri, S., Sato, K., Miyahara, R., et al. (2009) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0808-7 · Cited by 326 · see citing works

<i>EGFR</i> mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples

Ellison, G., Zhu, G., Moulis, A., Dearden, S., Speake, G., & McCormack, R. (2013) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2012-201194 · Cited by 301 · see citing works

Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression

Zhang, X., Zhang, S., Yang, X., Yang, J., Zhou, Q. H., Yin, L., An, S., Lin, J., Chen, S., Xie, Z., et al. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-188 · Cited by 296 · see citing works

ALK Expression Defines a Distinct Group of T/Null Lymphomas (“ALK Lymphomas”) with a Wide Morphological Spectrum

Falini, B., Bigerna, B., Fizzotti, M., Pulford, K. A. F., Pileri, S. A., Delsol, G., Carbone, A., Paulli, M., Magrini, U., Menestrina, F., et al. (1998) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)65629-5 · Cited by 275 · see citing works

Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohorts

Li, S., Li, L., Zhu, Y., Huang, C., Qin, Y., Liu, H., Ren‐Heidenreich, L., Shi, B., Ren, H. J., Chu, X., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.210 · Cited by 245 · see citing works

Mucinous Differentiation Correlates with Absence of EGFR Mutation and Presence of KRAS Mutation in Lung Adenocarcinomas with Bronchioloalveolar Features

Finberg, K. E., Sequist, L. V. D., Joshi, V. A., Muzikansky, A., Miller, J. M., Han, M., Beheshti, J., Chirieac, L. R., Mark, E. J., & Iafrate, A. J. (2007) · Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2007.060182 · Cited by 212 · see citing works

Frequency of Driver Mutations in Lung Adenocarcinoma from Female Never-Smokers Varies with Histologic Subtypes and Age at Diagnosis

Zhang, Y., Sun, Y., Pan, Y., Li, C., Shen, L., Li, Y., Luo, X., Ye, T., Wang, R., Hu, H., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2511 · Cited by 175 · see citing works

High Incidence of EGFR Mutations in Korean Men Smokers with No Intratumoral Heterogeneity of Lung Adenocarcinomas: Correlation with Histologic Subtypes, EGFR/TTF-1 Expressions, and Clinical Features

Sun, P.-L., Seol, H., Lee, H. J., Yoo, S. B., Kim, H., Xu, X., Jheon, S., Lee, C., Lee, J.-S., & Chung, J.-H. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182381515 · Cited by 163 · see citing works

Lung cancer in never-smoker Asian females is driven by oncogenic mutations, most often involving EGFR

Ha, S. Y., Choi, S., Cho, J. H., Choi, H. J., Lee, J., Jung, K., Irwin, D. L., Liu, X., Lira, M. E., Mao, M., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.2925 · Cited by 162 · see citing works

Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer

Paik, J. H., Choi, C., Kim, H., Jang, S. J., Choe, G., Kim, D. K., Kim, H. J., Yoon, H.-I., Lee, C., Jheon, S., et al. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2011.11.008 · Cited by 154 · see citing works

Distinct clinical features and outcomes in never‐smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement

Kim, H. R., Shim, H. S., Chung, J.-H., Lee, Y. J., Hong, Y. K., Rha, S. Y., Kim, S. H., Ha, S., Kim, S. K., Chung, K. S., et al. (2011) · Cancer · doi:10.1002/cncr.26311 · Cited by 149 · see citing works

Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR Coaltered Lung Adenocarcinoma

Cai, W., Lin, D., Wu, C., Li, X., Zhao, C., Zheng, L.-M., Chuai, S., Fei, K., Zhou, C., & Hirsch, F. R. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.8293 · Cited by 134 · see citing works

EGFR and EML4-ALK gene mutations in NSCLC: A case report of erlotinib-resistant patient with both concomitant mutations

Tiseo, M., Gelsomino, F., Boggiani, D., Bortesi, B., Bartolotti, M., Bozzetti, C., Sammarelli, G., Thai, E., & Ardizzoni, A. (2010) · Lung Cancer · doi:10.1016/j.lungcan.2010.11.014 · Cited by 125 · see citing works

KRAS mutations are associated with solid growth pattern and tumor-infiltrating leukocytes in lung adenocarcinoma

Rekhtman, N., Ang, D. C., Riely, G. J., Ladanyi, M., & Moreira, A. L. (2013) · Modern Pathology · doi:10.1038/modpathol.2013.74 · Cited by 117 · see citing works

Clinical Significance of EML4-ALK Fusion Gene and Association with EGFR and KRAS Gene Mutations in 208 Chinese Patients with Non-Small Cell Lung Cancer

Li, Y., Li, Y., Yang, T., Wei, S., Wang, J., Wang, M., Wang, Y., Zhou, Q., Liu, H., & Chen, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0052093 · Cited by 115 · see citing works

Nomogram to predict the presence ofEGFRactivating mutation in lung adenocarcinoma

Girard, N., Sima, C. S., Jackman, D. M., Sequist, L. V. D., Chen, H., Yang, J. C., Ji, H., Waltman, B. A., Rosell, R., Tarón, M., et al. (2011) · European Respiratory Journal · doi:10.1183/09031936.00010111 · Cited by 113 · see citing works

Histologic and cytomorphologic features of ALK-rearranged lung adenocarcinomas

Nishino, M., Klepeis, V. E., Yeap, B. Y., Bergethon, K. E., Morales‐Oyarvide, V., Dias-Santagata, D. C., Yagi, Y., Mark, E. J., Iafrate, A. J., & Mino-Kenudson, M. A. (2012) · Modern Pathology · doi:10.1038/modpathol.2012.109 · Cited by 112 · see citing works

Clinicopathological predictors of EGFR/KRAS mutational status in primary lung adenocarcinomas

Đačić, S., Shuai, Y., Yousem, S. A., Ohori, P. N., & Nikiforova, M. N. (2009) · Modern Pathology · doi:10.1038/modpathol.2009.154 · Cited by 108 · see citing works

Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose

Li, H., Pan, Y., Li, Y., Li, C., Wang, R., Hu, H., Zhang, Y., Ye, T., Wang, L., Shen, L., et al. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2012.09.018 · Cited by 104 · see citing works

Use of Epidermal Growth Factor Receptor/Kirsten Rat Sarcoma 2 Viral Oncogene Homolog Mutation Testing to Define Clonal Relationships Among Multiple Lung Adenocarcinomas

Girard, N., Deshpande, C. G., Azzoli, C. G., Rusch, V. W., Travis, W. D., Ladanyi, M., & Pao, W. J. (2009) · CHEST Journal · doi:10.1378/chest.09-0325 · Cited by 99 · see citing works

Correlation between morphology and EGFR mutations in lung adenocarcinomas

Ninomiya, H., Hiramatsu, M., Inamura, K., Nomura, K., Okui, M., Miyoshi, T., Okumura, S., Satoh, Y., Nakagawa, K., Nishio, M., et al. (2008) · Lung Cancer · doi:10.1016/j.lungcan.2008.04.017 · Cited by 99 · see citing works

Epidermal Growth Factor Receptor Mutation in Lung Cancer are Linked to Bronchioloalveolar Differentiation

Blons, H., Côté, J.-F., Corre, D. L., Riquet, M., Fabre, E., Laurent‐Puig, P., & Danel, C. J. (2006) · The American Journal of Surgical Pathology · doi:10.1097/01.pas.0000213285.65907.31 · Cited by 93 · see citing works

EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients

Bae, N. C., Chae, M. H., Lee, M. H., Kim, K. M., Lee, E. B., Kim, C. H., Park, T. I., Han, S. B., Jheon, S., Jung, T. H., et al. (2007) · Cancer Genetics and Cytogenetics · doi:10.1016/j.cancergencyto.2006.10.007 · Cited by 82 · see citing works

Good Response to Gefitinib in Lung Adenocarcinoma Harboring Coexisting EML4-ALK Fusion Gene and EGFR Mutation

Kuo, Y.-W., Wu, S., Ho, C., & Shih, J. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181f43274 · Cited by 79 · see citing works

De Novo Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in EGFR Mutation-Positive Patients with Non-small Cell Lung Cancer

Takeda, M., Okamoto, I., Fujita, Y., Arao, T., Ito, H., Fukuoka, M., Nishio, K., & Nakagawa, K. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181cee47e · Cited by 76 · see citing works

EGFR Mutation Testing in Patients with Advanced Non-Small Cell Lung Cancer: A Comprehensive Evaluation of Real-World Practice in an East Asian Tertiary Hospital

Choi, Y., Sun, J., Cho, J., Rampal, S., Han, J., Parasuraman, B. M., Güallar, E., Lee, G., Lee, J., & Shim, Y. M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056011 · Cited by 76 · see citing works

Detection and comparison of peptide nucleic acid-mediated real-time polymerase chain reaction clamping and direct gene sequencing for epidermal growth factor receptor mutations in patients with non-small cell lung cancer

Kim, H. J., Lee, K. Y., Kim, Y., Kim, K. S., Lee, S. Y., Jang, T. W., Lee, M. K., Shin, K. C., Lee, G. H., Lee, J. C., et al. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2011.08.005 · Cited by 75 · see citing works

Lung Adenocarcinoma with Concurrent Exon 19 EGFR Mutation and ALK Rearrangement Responding to Erlotinib

Popat, S., Araújo, A., Min, T., Swansbury, J. G., Dainton, M., Wotherspoon, A. C., Lim, E. K. S., Nicholson, A. G., & O'Brien, M. E. R. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31822eec5e · Cited by 71 · see citing works

Clinical and prognostic implications of ALK and ROS1 rearrangements in never-smokers with surgically resected lung adenocarcinoma

Kim, M. H., Shim, H. S., Kang, D. R., Jung, J. Y., Lee, C. Y., Kim, D. J., Lee, J. G., Bae, M. K., Kim, H. R., Lim, S. M., et al. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2014.01.003 · Cited by 65 · see citing works

ALK-Rearranged Lung Cancer in Chinese: A Comprehensive Assessment of Clinicopathology, IHC, FISH and RT-PCR

Li, Y., Pan, Y., Wang, R., Sun, Y., Hu, H., Shen, X., Lu, Y., Shen, L., Zhu, X., & Chen, H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0069016 · Cited by 60 · see citing works

Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: a case report

Holten‐Rossing, H., Grauslund, M., Urbanska, E. M., Melchior, L. C., Rask, C. K., Costa, J. C., Skov, B. G., Sørensen, J. B., & Santoni‐Rugiu, E. (2013) · BMC Research Notes · doi:10.1186/1756-0500-6-489 · Cited by 44 · see citing works

Association Between Age at Diagnosis and the Presence of EGFR Mutations in Female Patients with Resected Non-small Cell Lung Cancer

Choi, Y. H., Lee, J. K., Kang, H. J., Lee, T. S., Kim, C. H., Kim, C. H., Koh, J. S., Baek, H. J., Lee, J. C., & Na, I. I. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181f38816 · Cited by 44 · see citing works

Impact of age on epidermal growth factor receptor mutation in lung cancer

Ueno, T., Toyooka, S., Suda, K., Soh, J., Yatabe, Y., Miyoshi, S., Matsuo, K., & Mitsudomi, T. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2012.09.006 · Cited by 40 · see citing works

Analysis of Mutations in Epidermal Growth Factor Receptor Gene in Korean Patients with Non-small Cell Lung Cancer: Summary of a Nationwide Survey

Lee, S. H., Kim, W. S., Choi, Y. D., Seo, J., Han, J. H., Kim, M. J., Kim, L., Lee, G. K., Lee, C. H., Oh, M., et al. (2015) · Journal of Pathology and Translational Medicine · doi:10.4132/jptm.2015.09.14 · Cited by 33 · see citing works

Clinical characteristics associated with ALK rearrangements in never-smokers with pulmonary adenocarcinoma

Sun, J., Lira, M. E., Pandya, K., Choi, Y., Ahn, J. S., Mao, M., Han, J., Park, K., Ahn, M., & Kim, J. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.11.009 · Cited by 32 · see citing works

Clinical Likelihood of Sporadic Primary EGFR T790M Mutation in EGFR-Mutant Lung Cancer

Lee, Y., Lee, G. K., Hwang, J.-A., Yun, T., Kim, H. T., & Lee, J. S. (2014) · Clinical Lung Cancer · doi:10.1016/j.cllc.2014.09.002 · Cited by 28 · see citing works

KRAS Mutation Detection in Non-small Cell Lung Cancer Using a Peptide Nucleic Acid-Mediated Polymerase Chain Reaction Clamping Method and Comparative Validation with Next-Generation Sequencing

Lee, B., Lee, B., Han, G., Kwon, M. J., Han, J., & Choi, Y. (2014) · Journal of Pathology and Translational Medicine · doi:10.4132/koreanjpathol.2014.48.2.100 · Cited by 19 · see citing works

Relationship between EGFR mutations and clinicopathological features of lung adenocarcinomas diagnosed via small biopsies.

Kim, H. J., Choi, E. Y., Jin, H. J., & Shin, K. (2014) · PubMed · Cited by 14 · see citing works

Mucoepidermoid Carcinoma of Tracheobronchial Tree: Clinicopathological Study of 31 Cases

Ha, S. Y., Han, J., Lee, J. J., Kim, Y., Choi, Y., & Kim, H. K. (2011) · Journal of Pathology and Translational Medicine · doi:10.4132/koreanjpathol.2011.45.2.175 · Cited by 11 · see citing works

Epidermal Growth Factor Receptor Mutation Status in the Treatment of Non-small Cell Lung Cancer: Lessons Learned

Lee, K. H., Srimuninnimit, V., Cheng, R., Wang, X., & Orlando, M. (2015) · Cancer Research and Treatment · doi:10.4143/crt.2014.362 · Cited by 8 · see citing works

Clinicopathological predictors of EGFR/KRAS mutational status in primary lung adenocarcinomas

Galler, A. S., & Bauer, T. L. (2010) · Yearbook of Oncology · doi:10.1016/s1040-1741(10)79477-x · Cited by 4 · see citing works

Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy

Kobayashi, Y., & Mitsudomi, T. (2016) · Cancer Science · doi:10.1111/cas.12996 · Cited by 413 · see citing works

EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer

Hastings, K., Yu, H. A., Wei, W., Sánchez-Vega, F., DeVeaux, M., Choi, J., Rizvi, H. A., Lisberg, A. E., Truini, A., Lydon, C., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz141 · Cited by 362 · see citing works

Lung cancer in patients who have never smoked — an emerging disease

LoPiccolo, J., Gusev, A., Christiani, D. C., & Janne, P. A. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00844-0 · Cited by 307 · see citing works

Antitumour immunity regulated by aberrant ERBB family signalling

Kumagai, S., Koyama, S., & Nishikawa, H. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-020-00322-0 · Cited by 279 · see citing works

Emerging strategies to target RAS signaling in human cancer therapy

Chen, K., Zhang, Y., Qian, L. M., & Wang, P. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01127-w · Cited by 231 · see citing works

Prevalence and detection of low-allele-fraction variants in clinical cancer samples

Shin, H., Choi, Y., Yun, J. W., Kim, N. K. D., Kim, S., Jeon, H. J., Nam, J., Lee, C., Ryu, D., Kim, S. C., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01470-y · Cited by 202 · see citing works

The PI3K/Akt/mTOR pathway in lung cancer; oncogenic alterations, therapeutic opportunities, challenges, and a glance at the application of nanoparticles

Sanaei, M., Razi, S., Pourbagheri‐Sigaroodi, A., & Bashash, D. (2022) · Translational Oncology · doi:10.1016/j.tranon.2022.101364 · Cited by 204 · see citing works

Effects of mutations in Wnt/β-catenin, hedgehog, Notch and PI3K pathways on GSK-3 activity—Diverse effects on cell growth, metabolism and cancer

McCubrey, J. A., Rakus, D., Gizak, A., Steelman, L. S., Abrams, S. L., Lertpiriyapong, K., Fitzgerald, T. L., Yang, L. V., Montalto, G., Cervello, M., et al. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2016.09.004 · Cited by 149 · see citing works

Current therapy of KRAS-mutant lung cancer

Ghimessy, A., Radeczky, P., Laszlo, V., Hegedus, B., Renyi-Vamos, F., Fillinger, J., Klepetko, W., Lang, C., Dome, B., & Megyesfalvi, Z. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09903-9 · Cited by 115 · see citing works

Lung adenocarcinoma: from molecular basis to genome-guided therapy and immunotherapy

Chalela, R., Curull, V., Enríquez-Rodríguez, C. J., Pijuán, L., Bellosillo, B., & Gea, J. (2017) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.06.20 · Cited by 116 · see citing works

Targeting KRAS mutated non-small cell lung cancer: A history of failures and a future of hope for a diverse entity

Matikas, A., Mistriotis, D., Georgoulias, V., & Kotsakis, A. P. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.12.005 · Cited by 82 · see citing works

A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-Line Treatment for EGFR Mutation–Positive NSCLC Patients

Scagliotti, G. V., Moro‐Sibilot, D., Kollmeier, J., Favaretto, A. G., Cho, E. K., Grosch, H., Kimmich, M., Girard, N., Tsai, C., Hsia, T., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.10.003 · Cited by 78 · see citing works

Pulmonary invasive mucinous adenocarcinoma and mixed invasive mucinous/nonmucinous adenocarcinoma—a clinicopathological and molecular genetic study with survival analysis

Boland, J. M., Maleszewski, J. J., Wampfler, J. A., Voss, J. S., Kipp, B. R., Yang, P., & Yi, E. S. (2017) · Human Pathology · doi:10.1016/j.humpath.2017.08.002 · Cited by 61 · see citing works

Next-Generation Sequencing

Patel, S., Kadi, W., Walts, A. E., Marchevsky, A. M., Pao, A., Aguiluz, A., Mudalige, T., Liu, Z., Deng, N., & Lopategui, J. R. (2017) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2017.07.006 · Cited by 61 · see citing works

ALK in Non-Small Cell Lung Cancer (NSCLC) Pathobiology, Epidemiology, Detection from Tumor Tissue and Algorithm Diagnosis in a Daily Practice

Hofman, P. M. (2017) · Cancers · doi:10.3390/cancers9080107 · Cited by 59 · see citing works

Nrf2 and Notch Signaling in Lung Cancer: Near the Crossroad

Sparaneo, A., Fabrizio, F. P., & Muscarella, L. A. (2016) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/7316492 · Cited by 54 · see citing works

Recent Trends in Biosensing and Diagnostic Methods for Novel Cancer Biomarkers

Bommi, J. R., Kummari, S., Lakavath, K., Sukumaran, R. A., Panicker, L. R., Marty, J., & Goud, K. Y. (2023) · Biosensors · doi:10.3390/bios13030398 · Cited by 52 · see citing works

ALK rearrangements: Biology, detection and opportunities of therapy in non-small cell lung cancer

Rosas, G., Ruiz, R., Araujo, J. M., Pinto, J. A., & Mas, L. A. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.02.006 · Cited by 51 · see citing works

Frequent NRG1 fusions in Caucasian pulmonary mucinous adenocarcinoma predicted by Phospho-ErbB3 expression

Trombetta, D., Graziano, P., Scarpa, A., Sparaneo, A., Rossi, G., Rossi, A., Maïo, M. D., Antonello, D., Mafficini, A., Fabrizio, F. P., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.23800 · Cited by 49 · see citing works

Molecular Testing of Lung Cancers

Shim, H. S., Choi, Y., Kim, L., Chang, S. H., Kim, W. S., Roh, M. S., Kim, T. J., Ha, S. Y., Chung, J.-H., Jang, S. J., et al. (2017) · Journal of Pathology and Translational Medicine · doi:10.4132/jptm.2017.04.10 · Cited by 45 · see citing works

On target: Rational approaches to KRAS inhibition for treatment of non-small cell lung carcinoma

Lindsay, C. R., Garassino, M. C., Nadal, E., Öhrling, K., Scheffler, M., & Mazières, J. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.07.005 · Cited by 45 · see citing works

Distribution of EGFR Mutations in 10,607 Russian Patients with Lung Cancer

Имянитов, Е. Н., Демидова, И. А., Gordiev, M., Филипенко, М. Л., Kekeeva, T. V., Moliaka, Y. K., Анатольевна, Г. П., Kozhemyako, V. B., Vodolazhskiy, D. I., Sergeyeva, L. A., et al. (2016) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-016-0213-4 · Cited by 43 · see citing works

Clinicopathological, radiographic, and oncogenic features of primary pulmonary enteric adenocarcinoma in comparison with invasive adenocarcinoma in resection specimens

Zhao, L., Huang, S., Liu, J., Zhao, J., Li, Q., & Wang, H. (2017) · Medicine · doi:10.1097/md.0000000000008153 · Cited by 42 · see citing works

Large-Scale EGFR Mutation Testing in Clinical Practice: Analysis of a Series of 18,920 Non-Small Cell Lung Cancer Cases

Evans, M., O’Sullivan, B., Smith, M. R., Hughes, F., Mullis, T., Trim, N., & Tanière, P. (2018) · Pathology & Oncology Research · doi:10.1007/s12253-018-0460-2 · Cited by 37 · see citing works

Association of clock-like mutational signature with immune checkpoint inhibitor outcome in patients with melanoma and NSCLC

Chong, W., Wang, Z., Shang, L., Jia, S., Liu, J., Fang, Z., Du, F., Wu, H., Liu, Y., Chen, Y., et al. (2020) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2020.10.033 · Cited by 36 · see citing works

Anaplastic lymphoma kinase rearrangement in surgically resected stage IA lung adenocarcinoma

Shin, S. H., Lee, H. J., Jeong, B., Choi, Y. S., Shin, M.-H., Kim, S., Han, J., Lee, K. S., Shim, Y. M., Kwon, O. J., et al. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.05.131 · Cited by 34 · see citing works

Pulmonary adenocarcinoma with mucin production modulates phenotype according to common genetic traits: a reappraisal of mucinous adenocarcinoma and colloid adenocarcinoma

Sonzogni, A., Bianchi, F., Fabbri, A., Cossa, M., Rossi, G., Cavazza, A., Tamborini, E., Perrone, F., Busico, A., Capone, I., et al. (2017) · The Journal of Pathology Clinical Research · doi:10.1002/cjp2.67 · Cited by 32 · see citing works

Making NSCLC Crystal Clear: How Kinase Structures Revolutionized Lung Cancer Treatment

Vilachã, J. F., Mitchel, S. C., Akele, M. Z., Evans, S., & Groves, M. R. (2020) · Crystals · doi:10.3390/cryst10090725 · Cited by 29 · see citing works

The prognostic value of Kirsten rat sarcoma viral oncogene homolog mutations in resected lung adenocarcinoma differs according to clinical features

Ma, Z., Zhang, Y., Deng, C., Fu, F., Deng, L., Li, Y., & Chen, H. (2020) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2020.05.097 · Cited by 29 · see citing works

The expression, significance and function of cancer susceptibility candidate�9 in lung squamous cell carcinoma: A bioinformatics and in�vitro investigation

Gao, L., Guo, Y., Zeng, J., Ma, F., Luo, J., Zhu, H., Xia, S., Wei, K., & Chen, G. (2019) · International Journal of Oncology · doi:10.3892/ijo.2019.4758 · Cited by 27 · see citing works

Comparison of Epidermal Growth Factor Receptor Gene Mutations Identified Using Pleural Effusion and Primary Tumor Tissue Samples in Non–Small Cell Lung Cancer

Liu, N., Sun, R., Du, J., Dong, Q., Fan, C., Li, Q., Wang, E., & Liu, Y. (2017) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0000000000000543 · Cited by 22 · see citing works

Analysis of Predictive Biomarkers in Patients With Lung Adenocarcinoma From Southern Brazil Reveals a Distinct Profile From Other Regions of the Country

Andreis, T. F., Corrêa, B. D. S., Vianna, F. S. L., de Paris, F., Siebert, M., Leistner‐Segal, S., Hahn, E. C., Ulbrich, J. M., Rivero, L. F. D. R., de Oliveira, F. H., et al. (2019) · Journal of Global Oncology · doi:10.1200/jgo.19.00174 · Cited by 22 · see citing works

Landscape of Actionable Genetic Alterations Profiled from 1,071 Tumor Samples in Korean Cancer Patients

Lee, S., Lee, B., Shim, J., Lee, K. W., Yun, J. W., Kim, S.-Y., Kim, T., Kim, Y. H., Ko, Y. H., Chung, H. C., et al. (2018) · Cancer Research and Treatment · doi:10.4143/crt.2018.132 · Cited by 21 · see citing works

MicroRNA-370 inhibits the growth and metastasis of lung cancer by down-regulating epidermal growth factor receptor expression

Liu, X., Huang, Y., Jin, C., Zhou, Y., Chen, X., Li, J., Chen, Y., Li, M., Yao, Q., Li, K., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.21537 · Cited by 20 · see citing works

A Prospective Phase II Trial of First-Line Osimertinib for Patients With EGFR Mutation-Positive NSCLC and Poor Performance Status (OPEN/TORG2040)

Fukui, T., Mamesaya, N., Takahashi, T., Kishi, K., Yoshizawa, T., Tokito, T., Azuma, K., Morikawa, K., Igawa, S., Okuma, Y., et al. (2025) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2024.12.027 · Cited by 20 · see citing works

EGFR and KRAS molecular genotyping for pulmonary carcinomas: Feasibility of a simple and rapid technique implementable in any department of pathology

de Montpréville, V., Ghigna, M., Lacroix, L., Lemoine, A., Besse, B., Mercier, O. M., Fadel, É., Dorfmüller, P., & Chevalier, T. L. (2017) · Pathology - Research and Practice · doi:10.1016/j.prp.2017.03.011 · Cited by 19 · see citing works

Indoor Radon in EGFR- and BRAF-Mutated and ALK-Rearranged Non–Small-Cell Lung Cancer Patients

Mezquita, L., Benito, A., Ruano‐Raviña, A., Zamora, J., Olmedo, M. E., Reguera, P., Madariaga, A., Villamayor, M. L., Cortez, S. P., Gorospe, L., et al. (2019) · Clinical Lung Cancer · doi:10.1016/j.cllc.2019.04.009 · Cited by 18 · see citing works

Targeting KRAS in NSCLC: Old Failures and New Options for “Non-G12c” Patients

Jacobs, F., Cani, M., Malapelle, U., Novello, S., Napoli, V. M., & Bironzo, P. (2021) · Cancers · doi:10.3390/cancers13246332 · Cited by 17 · see citing works

Histology and oncogenic driver alterations of lung adenocarcinoma in Chinese.

Shang, G., Jin, Y., Zheng, Q., Shen, X., Yang, M., Li, Y., & Zhang, L. (2019) · PubMed Central · Cited by 17 · see citing works

Genotyping KRAS and EGFR Mutations in Greek Patients With Non-small-cell Lung Cancer: Incidence, Significance and Implications for Treatment

Linardou, H., Kotoula, V., Kouvatseas, G., Mountzios, G., Karavasilis, V., Samantas, E., Kalogera‐Fountzila, A., Televantou, D., Papadopoulou, K., Mavropoulou, X., et al. (2019) · Cancer Genomics & Proteomics · doi:10.21873/cgp.20155 · Cited by 16 · see citing works

Association between Contrast-Enhanced Computed Tomography Radiomic Features, Genomic Alterations and Prognosis in Advanced Lung Adenocarcinoma Patients

Rinaldi, L. M., Guerini‐Rocco, E., Spitaleri, G., Raimondi, S., Attili, I., Ranghiero, A., Cammarata, G., Minotti, M., Presti, G. L., Piano, F. D., et al. (2023) · Cancers · doi:10.3390/cancers15184553 · Cited by 14 · see citing works

EGFR mutation status in a series of Turkish non-small cell lung cancer patients

Calibasi‐Kocal, G., Amirfallah, A., Sever, T., Ünal, O. Ü., Gürel, D., Öztop, İ., Ellıdokuz, H., & Başbınar, Y. (2020) · Biomedical Reports · doi:10.3892/br.2020.1308 · Cited by 14 · see citing works

A Long Overdue Targeted Treatment for KRAS Mutations in NSCLC: Spotlight on Adagrasib

Brazel, D., Arter, Z., & Nagasaka, M. (2022) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s383662 · Cited by 15 · see citing works

The rapidly changing field of predictive biomarkers of non-small cell lung cancer

Tóth, L. J., Mokánszki, A., & Méhes, G. (2024) · Pathology & Oncology Research · doi:10.3389/pore.2024.1611733 · Cited by 14 · see citing works

EGFR and KRAS Mutations in the Non-Tumoral Lung. Prognosis in Patients with Adenocarcinoma

Chalela, R., Bellosillo, B., Curull, V., Longarón, R., Pascual-Guàrdia, S., Badenes‐Bonet, D., Arriola, E., Sánchez‐Font, A., Pijuán, L., & Gea, J. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8040529 · Cited by 13 · see citing works

PCR-based detection of EGFR, ALK, KRAS and BRAF mutations in Russian patients with lung adenocarcinoma: a single-center experience

Mitiushkina, N. V., Kholmatov, M. M., Venina, A. R., Tiurin, V. I., Yanus, G. A., Николаевна, С. Т., Yatsuk, O. S., Zaitseva, O. A., Ivantsov, A. O., Kuligina, E. S., et al. (2018) · Neoplasma · doi:10.4149/neo_2018_171225n843 · Cited by 12 · see citing works

Management of KRAS-Mutant Non-Small Cell Lung Cancer in the Era of Precision Medicine

Aredo, J. V., & Padda, S. K. (2018) · Current Treatment Options in Oncology · doi:10.1007/s11864-018-0557-6 · Cited by 11 · see citing works

Persist or resist: Immune checkpoint inhibitors in EGFR ‐mutated NSCLC

Zhu, P., Li, Z., Sun, Y., Liu, T., & Yin, R. H. (2024) · Cancer Science · doi:10.1111/cas.16428 · Cited by 10 · see citing works

The promise and challenges of deep learning models for automated histopathologic classification and mutation prediction in lung cancer

Patil, P. D., Hobbs, B. P., & Pennell, N. A. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.12.55 · Cited by 10 · see citing works

Landscape of EGFR mutations in lung adenocarcinoma: a single institute experience with comparison of PANAMutyper testing and targeted next-generation sequencing

Lee, J., Han, Y. B., Kwon, H. J., Lee, S. K., Kim, H., & Chung, J.-H. (2022) · Journal of Pathology and Translational Medicine · doi:10.4132/jptm.2022.06.11 · Cited by 8 · see citing works

Pulmonary Adenocarcinoma—Pathology and Molecular Testing

Pal, P., Cabanero, M., & Tsao, M. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-55433-6.00002-x · Cited by 5 · see citing works

Advanced-stage ALK-positive non–small-cell lung cancer (NSCLC) patients: Real-world treatment patterns and outcomes from the Italian biomarker ATLAS database

Reale, M. L., Scattolin, D., Vitale, A., Passiglia, F., Grisanti, S., Macerelli, M., Galetta, D., Sini, C., Minuti, G., Citarella, F., et al. (2025) · Lung Cancer · doi:10.1016/j.lungcan.2025.108762 · Cited by 4 · see citing works

Concomitance of EGFR mutations and ALK rearrangement in patients with Lung Cancer

Berradi, H., Kaanane, H., Kadmiri, N. E., & Nadifi, S. (2018) · Gene Reports · doi:10.1016/j.genrep.2018.03.018 · Cited by 4 · see citing works

Characteristics and immune checkpoint inhibitor effects on non-smoking non-small cell lung cancer with KRAS mutation

Wu, J.-J., Lee, P.-H., Zheng, Z.-R., Huang, Y.-H., Tseng, J., Hsu, K.-H., Yang, T., Yu, S., Chen, K., & Chang, G. (2022) · Medicine · doi:10.1097/md.0000000000029381 · Cited by 4 · see citing works

Epidermal Growth Factor Receptor Mutation Status and the Impact on Clinical Outcomes in Patients with Non-Small Cell Lung Cancer

Hm, H., wei, Y., Wang, J., Ran, F., Wen, Y., Chen, Q., & Bf, Z. (2022) · Balkan Journal of Medical Genetics · doi:10.2478/bjmg-2022-0015 · Cited by 4 · see citing works

Molecular characteristics and responses to EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients with EGFR exon 19 insertions

Li, Y., Ni, Y., Lv, F., Shi, Y., Chen, Y., Wu, X., Pang, J., Huang, L., Shao, Y. W., Wang, T., et al. (2025) · BMC Medicine · doi:10.1186/s12916-025-04075-1 · Cited by 3 · see citing works

EGFR mutation is positively correlated with C-Met protein expression: a study of 446 resected lung adenocarcinoma

Lei, H., Liu, L., Wei, J., Liu, Y., Ling, Y., Wang, X., Guo, L., Li, W., Ying, J., & Yang, L. (2021) · Translational Cancer Research · doi:10.21037/tcr-20-2202 · Cited by 3 · see citing works

Rationale and protocol design of a phase II study of first-line osimertinib treatment for patients with poor performance status and EGFR mutation-positive non-small cell lung cancer (OPEN/TORG2040)

Fukui, T., Sasaki, J., Igawa, S., Kada, A., Saito, T. I., Kogure, Y., Okamoto, H., & Naoki, K. (2022) · BMC Cancer · doi:10.1186/s12885-022-10409-6 · Cited by 3 · see citing works

Risk factors and actionable molecular signatures in COVID-19-associated lung adenocarcinoma and lung squamous cell carcinoma patients

Ullah, M. A., Alam, S., Moin, A. T., Ahamed, T., & Shohael, A. M. (2023) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2023.106855 · Cited by 3 · see citing works

Characteristics and prognostic analysis of patients with detected KRAS mutations in resected lung adenocarcinomas by peptide nucleic acid-locked nucleic acid polymerase chain reaction (PNA-LNA PCR) clamp method

Hashimoto, T., Owada, Y., Katagiri, H., Yakuwa, K., Tyo, K., Sugai, M., Fuzimura, I., Utsumi, Y., Akiyama, M., Nagashima, H., et al. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-23-15 · Cited by 3 · see citing works

Association between clinical characteristics and the diagnostic accuracy of circulating single‐molecule amplification and resequencing technology on detection epidermal growth factor receptor mutation status in plasma of lung adenocarcinoma

Shi, C., Zheng, Y., Li, Y., Sun, H., & Liu, S. (2017) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.22271 · Cited by 3 · see citing works

Targeted therapy for older patients with an oncogene driven non-small cell lung cancer: Recommendations from a SIOG expert group

Decoster, L., Camidge, D. R., Fletcher, J. A., Addeo, A., Greystoke, A., Kantilal, K., Bigay-Game, L., Kanesvaran, R., & Gomes, F. (2025) · Lung Cancer · doi:10.1016/j.lungcan.2025.108087 · Cited by 2 · see citing works

Site-Specific Inflammatory Signatures in Metastatic NSCLC: Insights from Routine Blood Count Parameters

Vornicu, V.-N., Negru, A. G., Vonica, R. C., Cosma, A. A., Săftescu, S., Fenesan, M. P., & Cîmpean, A. M. (2025) · Medicina · doi:10.3390/medicina61091521 · Cited by 2 · see citing works

From G12C To pan-RAS: The expanding therapeutic landscape of KRAS-mutant NSCLC

Canaslan, K., Başbınar, Y., & Öztop, İ. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105344 · Cited by 2 · see citing works

Exploring the conformational space of ROS1 kinase domain and the impact of allosteric mutations

Haq, F. U., Vilachã, J. F., de Beeck, K. O., Camp, G. V., Marrink, ‪. J., & Vandeweyer, G. (2025) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2024.2448677 · Cited by 1 · see citing works

Dual EGFR L858R and KRAS G12A Mutations in Lung Adenocarcinoma: A Rare Case Report and Literature Review

Wei, G., Tang, J., Wang, H., & Zhang, D. (2025) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s531038 · Cited by 1 · see citing works

Ultrarapid EGFR Testing in Non–Small Cell Lung Carcinoma Patients: Findings From a Canadian Clinical Testing Workflow

Fitzsimmons, K. C., Hughesman, C. B., Pataky, R. E., Weymann, D., D'Amours, M.-F., Alex, D., Ionescu, D. N., Melosky, B., Carolan, H., McNeil, K., et al. (2025) · Laboratory Investigation · doi:10.1016/j.labinv.2025.104245 · Cited by 1 · see citing works

The role of oncogenes and tumor suppressor genes in determining survival rates of lung cancer patients in the population of North Sumatra, Indonesia

Soeroso, N. N., Ananda, F. R., Sitanggang, J. S., & Vinolina, N. S. (2022) · F1000Research · doi:10.12688/f1000research.113303.1 · Cited by 1 · see citing works

Real-World Data on Treatment Outcome of ALK-Positive Non-Small Cell Lung Cancer from an Indian Multicentric Cancer Registry

Moharana, L., Panda, S. S., Devaraj, S., Biswas, G., Subudhi, G. C., Parida, P. K., Mishra, S. K., Pattnaik, J., Mohanty, S. K., Karunanidhi, S., et al. (2023) · South Asian Journal of Cancer · doi:10.1055/s-0043-1776290 · Cited by 1 · see citing works

Mutually exclusive driver mutations identifies 2 separate primaries in a collision tumor initially interpreted as a solitary lung adenocarcinoma with tumor heterogeneity

Torrez, M. M., Sheibani, K., & Vasef, M. A. (2024) · Respiratory Medicine Case Reports · doi:10.1016/j.rmcr.2024.101986 · Cited by 1 · see citing works

Improved platelet separation performance from whole blood using an acoustic fluidics system

Sakai, K., Ohara, S., Tanaka, J., Suda, K., Muramatsu, T., Uematsu, C., Tsutani, Y., Mitsudomi, T., & Nishio, K. (2024) · Cancer Science · doi:10.1111/cas.16337 · Cited by 1 · see citing works

Mutations in the exons of epidermal growth factor receptor gene are associated with clinicopathological features of lung cancer

Wan, Y., Wang, Y., Fang, F., Wu, G., & Zhang, M. (2020) · Asian Journal of Surgery · doi:10.1016/j.asjsur.2020.06.015 · Cited by 1 · see citing works

The role of oncogenes and tumor suppressor genes in determining survival rates of lung cancer patients in the population of North Sumatra, Indonesia

Soeroso, N. N., Ananda, F. R., Sitanggang, J. S., & Vinolina, N. S. (2023) · F1000Research · doi:10.12688/f1000research.113303.2

Back Pain Served as a Clue to the Detection of Lung Cancer in a Young Adult

Morimoto, J., Sasaki, A., Nagato, K., Sugano, I., & Kimura, H. (2018) · Haigan · doi:10.2482/haigan.58.275

ALK-rearranged primary mixed mucinous and non-mucinous lung adenocarcinoma: A case report

González, D., Castañeda-Motta, C., Romero-Rojas, A. E., Carvajal, C., & Parra-Medina, R. S. (2025) · Revista Española de Patología · doi:10.1016/j.patol.2024.100796

Unveiling unique protein and phosphorylation signatures in lung adenocarcinomas with and without ALK , EGFR , and KRAS genetic alterations

Bugyi, F., Balbisi, M., Sugár, S., Váncza, L., Regős, E., Kovalszky, I., Laczó, I., Harkó, T., Kecskeméti, G., Szabó, Z., et al. (2025) · Molecular Oncology · doi:10.1002/1878-0261.70091

Concordance study of bronchial biopsy tissues and matched bronchial brushing cytology specimens in driver gene detection of non-small cell lung cancer

Li, X., Chen, L., Niu, P., Wang, J., Sun, X. G., Lu, N., & Weng, Y. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1842742

A Narrative Review of the Cases of Co-altered EGFR and ALK in Non-small Cell Lung Cancers: An Attempt to Break the Therapeutic Dilemma

Upadhyay, A. K., Kumar, M., Prakash, A., & Purkait, J. (2026) · Cureus · doi:10.7759/cureus.117425

Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement.

源��꽭洹�, 源��꽭�썕, 源�二쇳빆, 源��삙�젴, �씪�꽑�쁺, �떖�슚�꽠, �젙寃쎌쁺, 議곕퀝泥�, & �솉�쑄寃� (2012) · YUHSpace (Yonsei University Medical Library)

Analysis of real-word mutations of lung cancer driver genes in five regions of China

Sun, M., Guo, Y., Shao, G., Duan, X., Yang, Z., Zhang, P., Liu, Y., Dong, Y., Wang, X., Xu, Y., et al. (2019) · Translational Cancer Research · doi:10.21037/tcr.2019.10.28 · Cited by 8 · see citing works

Comprehensive Molecular Analysis of NSCLC; Clinicopathological Associations

Chatziandreou, I., Tsioli, P., Sakellariou, S., Mourkioti, I., Giannopoulou, I., Levidou, G., Korkolopoulou, P. A., Patsouris, E., & Saetta, A. A. (2015) · PLoS ONE · doi:10.1371/journal.pone.0133859 · Cited by 41 · see citing works

Clinical features associated with epidermal growth factor receptor and K-RAS gene mutations in non-small cell lung cancer

Žemaitis, M., Meister, M. A., Dienemann, H., Fischer, �., Manegold, C., Sakalauskas, R., & Lahm, H. (2006) · Lithuanian University of Health Sciences

EGFR and KRAS mutations in Turkish non-small cell lung cancer patients: a pilot study

Bircan, S., Baloğlu, H., Küçükodacı, Z., & Bircan, A. (2014) · Medical Oncology · doi:10.1007/s12032-014-0087-4 · Cited by 22 · see citing works